HLA class II transgenic mice as models of human diseases

Immunological Reviews

Volumn 169, Issue , 1999, Pages 67-79

  Taneja, Veena ^a   David, Chella S ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN; T LYMPHOCYTE RECEPTOR;

AUTOIMMUNE DISEASE; CELL SELECTION; DISEASE MODEL; DISEASE PREDISPOSITION; HUMAN; IMMUNE RESPONSE GENE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; GENES, MHC CLASS II; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; HYPERSENSITIVITY; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; POLYCHONDRITIS, RELAPSING; SELECTION (GENETICS); THYROIDITIS, AUTOIMMUNE; VACCINES;

EID: 0032776148     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01307.x     Document Type: Review

References (101)

1. 1. Nelson JL, Hansen JA. Autoimmune diseases and HLA. Crit Rev Immunol 1990;10:307-328.
2. 2. Mitchison NA. Specialization, tolerance, memory, competition, latency, and strife among T cells. Annu Rev Immunol 1992;10:1-12.
3. 3. Möller E, Böhme J, Valugerdi MA, Ridderstad A, Olerup O. Speculations on mechanisms of HLA association with autoimmune diseases and the specificity of "autoreactive" T lymphocytes. Immunol Rev 1990;118:5-20.
4. 4. Todd JA, Bell JI, McDevitt HO. HLA-DQB gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987;329:599-604.
5. 5. Stastny P. Association of the B cell alloantigen DRW4 with rheumatoid arthritis. N Engl J Med 1978;298:869-871.
6. 6. Tiwari JL, Terasaki PI. Endocrinology, In: Tiwari JL, Terasaki PI, eds. HLA and disease associations New York: Springer Verlag: 1985. p. 185-231.
7. 7. Oksenherg JR, Begovich AB, Erlich HA, Lawrence S. Genetic factors in multiple sclerosis. JAMA 1993;170:2362-2369.
8. 8. Olerup O, et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: Two immunogenetically distinct disease entities. Proc Natl Acad Sci USA 1989;86:7113-7117.
9. 9. McCusker CT, Reid B, Green D, Gladman DD, Buchanan WW, Singal DP. HLA-D region antigens in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:192-197.
10. 10. Parry S, Olson J, Patel S, Noble J, Erlich H, Sonderstrup-McDevitt G. Differential function of HLA-DR4 alleles in type I diabetes mellitus (IDDM). In: Keystone Symposia. Immunogenetics of Human Disease-MHC/TCR and Peptide; 1999 Jan 16-22,Taos (NM). 1999. p. 51.
11. 11. Lawrence SK, et al. Transgenic HLA-DRα faithfully reconstitutes IE-controlled immune functions and induces cross-tolerance to Eα in Eα" minant mice. Cell 1989;58;583-594.
12. 12. Straub G, Vignali DAA, Schonrich G, Hammerling GJ, Negative and positive selection hy HLA-DR3 (Drw 17) molecules in transgenic mice. Immunogenetics 1994;40:104-108.
13. + single transgenic mouse. J Immunol 1991;146:854-859.
14. + T cells in transgenic mice. Immunogenetics 1992;35:219-223.
15. 15. Nishimura Y, et al. Expression of the human MHC, HLA-DQW6 genes alters the immune response in C57BI./6 mice. J Immunol 1990;145:353-360.
16. 16. Fugger L, Michie SA, Rulifson I, Lock CB, McDevitt GS. Expression of HLA-DR4 and human CD-4 transgenes in mice determines the variable region β-chain T cell repertoire and mediates an HLA-DR restricted immune response. Proc Natl Acad Sci USA 1994;91:6151-6155.
17. 17. Yeung RSM, et. al. Human CD4-major histocompatibility complex class II (DQW6) transgenic mice in an endogenous CD4/CD8-deficient background: reconstitution of phenotype and human-restricted function. J Exp Med 1994;180:1911-1920.
18. 18. Altmann DM, Douek DC, Prater AJ, Hetherington CM, Inoko H, Elliot JI. The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4. J Exp Med 1994;181:867-875.
19. 19. Yamamoto K, et al. Function interaction between human histocompatibility leukocyte antigen (HLA) class II and mouse CD4 molecule in antigen recognition by T cells in HLA-DR and DQ transgenic mice. J Exp Med 1994;180:165-171.
20. 20. Gosgrove D, et al, Mice lacking MHC Class II molecules. Cell 1991;66:1051-1066.
21. 21. Geluk A, et al. Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice. Proc Natl Acad Sci USA 1998;95:10797-10802.
22. 22. Gregersen PK, Silver J. Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis, Arthritis Rheum 1987;30:1205-1113.
23. 23. Lanchbury JSS, Sakkas LI, Marsh SGE, Bodmer JG, Welsh KI, Panayi GS. HLA-DQB3.1 is a determinant of susceptibility to DR4 associated rheumatoid arthritis Hum Immunol 1989;26:59-71.
24. 24. Singal DP, D'Souza M, Reid B, Bensen WG, Kassam YB, Adachi JD. HLA-DQ β-chain polymorphism in HLA-DR4 haplotypes associated with rheumatoid arthritis. Lancet 1987;2:1118-1120.
25. 25. Taneja V, Mehra NK, Chandershekaran AN, Ahuja RK, Singh YN, Malaviya AN. HLA-DR4-DQw8, but not DR4-DQw7 haplotypes occur in Indian patients with rheumatoid arthritis. Rheumatol Int 1992;11:251-255.
26. 26. Trentham DE, Towens A, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977;146:857-868.
27. 27. Trentham DE, Collagen induced arthritis as a relevant model for rheumatoid arthritis: evidence pro and con. Arthritis Rheum 1982;25:911-914.
28. 28. Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen induced arthrits in mice: 1. Major histocompatibility complex (I-region) linkage and antibody correlates. J Exp Med 1981;154:688-700.
29. 29. Gonzalez-Gay MA, et al. Protective role of major histocompatibility complex class II Ebd transgene on collagen-induced arthritis. J Exp Med 1994;180:1559-1564.
30. 30. Taneja V, Hanson J, Smart MK, Griffiths MM, Luthra HS, David CS. Expression of the H2-E molecule mediates protection to collagen-induced arthritis in HLA-DQ8 transgenic mice: role of cytokines. Int Immunol 1997;9:1213-1219.
31. 31. Gonzalez-Gay MA, et al. Polymorphism of the MHC class II Eb gene determines the protection against collagen induced arthritis. Immunogenetics 1995;42:35-41.
32. 32. Zanelli E, Gonzalez-Gay MA, David CS. Could HLA-DRB1 be the protective locus in rheumatoid arthritis? Immunol Today 1995;16:274-278.
33. 33. Nabozny GH, et al. HLA-DQ8 transgenic mice are highly susceptible to collagen induced arthritis: a novel model for human polyarthritis. J Exp Med. 1996;183:27-37.
34. 34. Bradley DS, et al, HLA-DQBI polymorphism determine incidence, onset and severity of collagen-induced arthritis (CIA) in transgenic mice: implications in human rheumatoid arthritis. J Clin Invest 1997;100:2227-2234.
35. 35. Krco CJ, Harders J, Watanabe S, Griffiths M, Luthra HS, David CS. Identification of T cell epitopes on human type II collagen using HLA-DQ8 and HLA-DQ6 transgenic mice. J Immunol (In press).
36. 36. Rosloniec EF, et al. Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J Immunol 1998;160:2573-2578.
37. 37. Taneja V, Pan S, Griffiths MM, Luthra H, David CS. Complementation between HLA-DRB1*0401 and specific H2A molecule leads to collagen induced arthritis. Hum Immunol (In press).
38. 38. Taneja V. Griffiths MM, Luthra H, David CS. Modulation of HLA-DQ-restricted collagen-induced arthritis by HLA-DRB1 polymorphism. Int Immunol 1998;10:1449-1457.
39. 39. Salvat S, et al. Tolerance to a self-peptide from the third hypervariable region of HLA DRB1*0401 in rheumatoid arthritis patients and normal subjects. J Immunol 1994;153:5321-5329.
40. 40. Hjelmstrom P, DeWeese-Scott C, Penzotti JE, Lybrand TP. Sanjeevi CB. Structural differences between HLA-DQ molecules associated with myasthenia gravis characterized by molecular modeling. J Neuroimmunol 1998;85:102-105.
41. 41. Matsushita S, et al. HLA-DQ binding motifs, Comparative analysis of type II collagen-derived peptides to DR and DQ molecules of rheumatoid arthritis-susceptible and non-susceptible haplotypes. Int Immunol 1996;8:757-764.
42. 42. Steele JC, Young SP, Goodall JC, Gallimore PH. Structural aspects of the interaction between heterogeneic human papillomavirus type 1 E4-specific T cell receptors and the same peptide/HLA-DQ8 complex. J Immunol 1998;161:4745-4752.
43. 43. Vogt AB, et al. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J Immunol 1994;153:1665-1673.
44. 44. Chicz RM, Lane WS, Robinson RA, Trucco M, Strominger JL, Gorga JC. Self-peptides bound to the type I diabetes associated class II MHC molecules HLA-DQ1 and HLA-DQ8. Int Immunol 1994;6:1639-1649.
45. 45. Zanelli E, Krco CJ. Baisch JM, Chengs S, David CS. Immune response of HLA-DQ8 transgenic mice to peptides from the third hypervariable region of HLA-DRB1 correlates with predisposition to rheumatoid arthritis. Proc Natl Acad Sci USA 1996;93:1814-1819.
46. 46. Zanelli E, Krco CJ, David CS. Critical residues on HLA-DRB1*0402 HV3 peptide for HLA-DQ8-restricted immunogenicity: implications for rheumatoid arthritis predisposition. J Immunol 1997;158:3545-3551.
47. 47. Das P, Bradley DS, Geluk A, Griffiths MM, Luthra HS, David CS. An HLA-DRB1*0402 derived peptide (HV3 65-79) prevents collagen-induced arthritis in HLA-DQ8 transgenic mice. Arthritis Rheum 1997;40:s72.
48. 48. Nishimoto H, Kikutani H, Yamamura K, Kishimoto T. Prevention of autoimmune insulitis by expression of I-E molcules in NOD mice. Nature 1987;328:432-434.
49. 49. Slattery RM, Kjer-Nielsen L. Allison J, Charlton B, Mandel TE, Miller JF. Prevention of diabetes in non-obese diabetic I-Ak transgenic mice. Nature 1990;345:724-726.
50. 50. Lund T, et al. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A β-chain or normal I-E α-chain. Nature 1990;345:727-729.
51. 51. Wicker LS, et al. Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic; for the Type 1 diabetes-associated human MHC class II allele, DRB1*0401. J Clin Invest 1996;98:2597-2603.
52. 52. Patel SD, et al. Identification of immunodomainant T cell epitopes of human glutamic acid decarboxylase 65 hy using HLA-DR (alpha*0101, beta*0401) transgenic mice. Proc Natl Acad Sci USA 1997;94:8082-8087.
53. 53. Herman A, et al. Epitopes of human glutamic acid decarboxylase 65 presented by a diabetes-susceptible HLA-DQ molecule. In: Keystone Symposia. Immunogenetics of Human Disease-MHC/TCR and Peptide; 1999 Jan 16-22; Taos (NM). 1999. p. 49.
54. 54. Abraham RS, Kudva YC, Wilson SB, Strominger JL, David CS. DR3/DQ8 Aβo transgenic mice develop spontaneous insulitis and loss of tolerance to GAD 65. In: Keystone Symposia, Immunogenetics of Human Disease-MHC/TCR and Peptide; 1999 Jan 16-22;Taos (MM). 1999. p. 46.
55. 55. Raju R, Munn SR, David CS. T cell recognition of human pre-proinsulin peptides depends on the polymorphism at HLA DQ locus: a study using HLA DQ8 and DQ6 transgenic mice. Hum Immunol 1997;58:21-29.
56. 56. Congia M, Patel S, Cope AP, De Virgiliis S, Sonderstrup G. T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin. Proc Natl Acad Sci USA 1998;95:3833-3838.
57. 57. Kudva YC, Deng Y-J, Abraham RS, Notkins AL, David CS. The cytoplasmic region of IA-2 is imunogenic in NOD and HLA-DQ8 transgenic mice. In: Keystone Symposia, Immunogenetics of Human Disease-MHC/TCR and Peptide; 1999 Jan 16-22;Taos (NM). 1999. p. 50.
58. 58. Ettinger RA, Liu AW, Nepom GT, Kwok WW. Exceptional stability of the HLA-DQA1*0102/DQB1*0602 αβ protein dimer. the class 11 MHC molecule associated with protection from insulin-dependent diabetes mellitus. J Immunol 1998;161:6439-6445.
59. 59. Jersild C, Fog T, Hansen GS, Thomsen M, Svejgaard A, Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973;2:1221-1225.
60. 60. Spurkland A, Ronningen KS, Vandvik B, Thorsby E, Vartdal F. HLA-DQA1 and HLA-DQB1 genes may jointly determine susceptibility to develop multiple sclerosis. Hum Immunol 1991;30:69-75.
61. 61. Stewart GJ, Mcleod JG, Basten A, Bashir HV. HLA family studies and multiple sclerosis: a common gene, dominantly expressed. Hum Immunol 1981;3:13-29.
62. 62. Coraddu F, et al DA. HLA associations with multiple sclerosis in the Canary Islands. J Neuroimmunol 1998;87:130-135.
63. 63. Weinshenker BG, et al. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. J Neurology 1998;51:742-747.
64. 64. Ito K, et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 1996;183:2635-2644.
65. 65. Das P, Drescher K, Bradley DS, Reviera-Quinones C, Rodriguez M, David CS. HLA transgenic mice as humanized models of multiple sclerosis (MS): studies on EAE. Hum Immunol 1997;55 (Suppl 1):4.
66. 66. O'Brien RM, Thomas WR, Wooton AM. T cell responses to the putrified major allergens from the house dust mite Dermatophagoides pteronyssinus. J Allergy Clin Immunol 1992;89:1021-1026.
67. 67. Joost van Neerven R, et al. T cell epitopes of house dust mite major allergen Der p IIJ. J Immunol 1993;151:2326-2331.
68. 68. Verhoef A, et al. Clonal analysis of the atopic immune response to the group 2 allergen of Dermatophagoides spp: identification of HLA-DR and DQ restricted T cell epitopes, Int Immunol 1993;5:1589-1594.
69. 69. Neeno T, Krco CJ, Harders J, Baisch J, Cheng S, David CS. HLA-DQ8 transgenic mice lacking endogenous class II molecules respond to house dust allergens. J Immunol 1996;156:3191-3195.
70. 70. Ghosh B. Perry MP, Marsh DG. Cloning the cDNA encoding the AmbtV allergen from giant ragweed (Ambrosia trifida) pollen. Gene 1991;101:231-238.
71. 71. Kafnar T, et al. Expression and analysis of recombinant Amb a V and Amb t V allergens. Comparison with native proteins by immunological assays and NMR spectroscopy. J Biol Chem 1992;267:21119-21123.
72. 72. Ghosh B, Perry MP, Rafnar T, Marsh DG. Cloning and expression of immunologically active recombinant Amb a V allergen of short ragweed (Ambrosia artemisiifolia) pollen. J Immunol 1993;150:5391-5399.
73. 73. Marsh DG, Huang SK. Molecular genetics of human immune responsiveness to pollen allergens. Clin Exp Allergy 1991;21(Suppl 1):168-172.
74. 74. Huang SK, Marsh DG. Genetics of allergy. Ann Allergy 1993;70:347-358.
75. 75. Blumenthal M, Marcus-Bagley D, Awdeh Z, Johnson B, Yunis KJ, Alper CA. HU-DR2, [HLA-B7, SC31, DR2], and [HL4-B8, SC01, DR3] haplotypes distinguish subjects wilh asthma from those with rhinitis only in ragweed pollen allergy. J Immunol 1992;148:411-416.
76. 76. Zwollo P, Ehrlich-Kautzky E, Scharf SJ, Ansari AA, Erlich HA, Marsh DG. Sequencing of HLA-D in responders and nonresponders to short ragweed allergen, Amb a V. Immunogenetics 1991;33:141-151.
77. 77. Chapoval SP, Krco CJ, Harders J, David CS. HLA-DQ6 and HLA-DQ8 transgenic mice respond to ryegrass allergen and recognize different epitopes on its major antigen. J Immunol 1998;161:2032-2037.
78. 78. Chapoval SP, et al. Immune response of HLA-DQ transgenic mice to Ragweed Allergens; A Humanized mouse model for ragweed allergy. J Allergy Clin Immunol 1998;101:S152.
79. 79. Pearson CM, Kline HM, Newcomer VD. Relapsing polychondritis. N Engl J Med 1960;263:51-54.
80. 80. McAdam LP, O'Hanlan MA, Bluestone R. Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine 1976;55:193-215.
81. 81. Zeuner M, Straub RH. Rauh G, Albert ED, Sacholmerich J, Lang B. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol 1997;24:96.
82. 82. Isaak BL, Leisegang TJ, Michel CJ Jr. Ocular and systemic findings in relapsing polychondritis. Ophthalmology 1986;93:681.
83. 83. Foidart JM, et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med 1978;299:1203.
84. 84. Terato K, et al. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum 1990;33:1493-1500.
85. 85. Lang B, et al. Susceptibility to relapsing polychondritis is associated with HLA-DR4. Arthritis Rheum 1993;36:660-664.
86. 86. Bradley DS, Das P, Griffiths MM, Luthra HS, David CS. HLA-DQ6/8 double transgenic mice develop auricular chondritis following type II collagen immunization; a model for human relapsing polychondritis, J Immunol 1998;161:5046-5053.
87. 87. Bell J, et al. HLA-DQ β chain polymorphism linked to myasthenia gravis. Lancet 1986;1:1058-1060.
88. 88. Kaul R, Shenoy M, Christadoss P. The role of major histocompatibility complex genes in myasthenia gravis and experimental autoimmune myasthenia gravis pathogenesis. Adv Neuroimmunol 1994;4:387-402.
89. 89. Tola MR, et al. Immunogenetic heterogeneity and associated autoimmune disorders in myasthenia gravis: a population-based survey in the province of Ferrara, northern Italy. Acta Neurol Scand 1994;90:318-323.
90. 90. Barton EN. Smikle M, Moran OS, Myasthenia gravis and HLA phenotypes in Jamaicans. South Med J 1992;85:904-906.
91. 91. Carlsson B, Wallin J, Pirskanen R, Matell G, Smith CIE. Different HLA-DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics 1990;31:285-290.
92. 92. Hjelstrom P, et al. Different HLA-DQ are positively and negatively associated in Swedish patients with myasthenia gravis. Autoimmumity 1995;22:59-65.
93. + cells sensitized to nicotinic acetylcholine receptor. J Immunol 1991;147:1484-1491.
94. 94. Raju R, Zhan WZ, Karachunski P, Conti-Fine B, Sieck GC, David C. Polymorphism at the HLA-DQ locus determines susceptibility to experimental autoimmune myasthenia gravis. J Immunol 1998;160:4169-4174.
95. 95. Raju R. Zhan W-Z, Karachunski P, Sieck GC, Conti-Fine BM, David CS. Susceptibility of HLA-DR3 transgenic mice to experimental autoimmune myasthenia gravis, Ann N Y Acad Sci 1998;841:360-364.
96. 96. Beisel KW, David CS, Giraldo AA, Kong YM, Rose NR. Regulation of experimental autoimmune thyroiditis: mapping of susceptibility to the I-A subregion of the mouse H-2. Immunogenetics 1982;15:417-430.
97. 97. Moens H, Farid NR. Hashimoto's thyroiditis is associated with HLA-DRw3. N Engl J Med 1978;299:133-134.
98. 98. Farid NR, Sampson L, Moens H, Barnard JM. The association of goitrous autoimmune thyroiditis with HLA-DR5. Tissue Antigens 1981;17:265-268.
99. 99. Tandon N, Zhang L, Weetman AP. HLA associations with Hashimoto's thyroiditis. Clin Endocrinol 1991;34:383-386.
100. 100. Kong YM, et al. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA DRB1*0301 (DR3) gene. J Exp Med 1996;184:1167-1172.
101. 101. Bagavani H, Fusi FM, Baisch J, Kurth B, David CS, Tung KSK. Immunogenicity and contraceptive potential of a human zona pellucida 3 peptide vaccine. Biol Reprod 1997;56:764-770.